Global cancer medicines: what future?

The ICP has developed significant expertise in the analysis of cancer drug research linked to major public policy issues around clinically meaningful endpoints, regulatory public policy and the link between public policy in cancer drug development and affordable cancer care systems.

In addition to our work looking atcancer medicines in high income countrieswe are also working with partners on key issues in emerging economies, for example access to medicines in Latin America and the cost of cancer medicines for children in low and middle income countries. The ICP is also developing a program to look at the Cuban system for global cancer medicines as well as their contribution to cancer global health. For 2015 we will be analysing the political economy of global cancer medicines as part of the WHO Essential Medicines List.